Use of Boussignac Continuous Positive Airway Pressure to Reduce Intubation in Adults with Acute Hypoxemic Respiratory Failure in Burkina Faso

What this Trial Is About

Researchers are evaluating the use of Continuous Positive Airway Pressure CPAP with a Boussignac valve in adults experiencing acute hypoxemic respiratory failure ARF, a serious emergency often requiring intensive care and invasive mechanical ventilation. This trial is focused on settings like Burkina Faso, where access to invasive ventilation is limited, and non-invasive supports such as CPAP could reduce the need for intubation and improve patient outcomes. Participants will be randomly assigned to one of two groups within three hours of meeting inclusion criteria. The CPAP group will receive continuous CPAP using a Boussignac device for 6 to 12 hours, followed by intermittent use based on tolerance, alongside standard oxygen therapy. The standard group will receive oxygen therapy via nasal prongs or masks until intubation criteria are met, death occurs, or oxygen is no longer needed. Treatment adjustments and intubation decisions depend on clinical status and resource availability. During the study, participants will be monitored for intubation criteria over 7 days, oxygenation levels, and safety of CPAP use. Other assessments include mortality at 28 days, hospital stay duration, organ failure-free days, and CPAP tolerance. The study will take place in four university hospitals in Burkina Faso, involving emergency and intensive care departments, with follow-up evaluations and data collection conducted accordingly.

Continous Positive Airway Pressure (CPAP) Support for Acute Hypoxemic Respiratory Failure in Burkina Faso